Kinesin Inhibitor

Kinesin Inhibitors (36):

Cat. No.	Product Name	Effect	Purity

HY-50759

Ispinesib	Inhibitor	99.62%
Ispinesib is a specific inhibitor of kinesin spindle protein (KSP), with a K_{i app} of 1.7 nM.

HY-15187

Filanesib	Inhibitor	98.23%
Filanesib (ARRY-520) is a selective and noncompetitive kinesin spindle protein (KSP) inhibitor, with an IC₅₀ of 6 nM for human KSP. Filanesib induces cell death by apoptosis in vitro. Filanesib has potent anti-proliferative activity.

HY-10299

GSK-923295	Inhibitor	99.82%
GSK-923295 is a special, allosteric inhibitor of centromere-associated protein-E (CENP-E) kinesin motor ATPase activity, with K_i of 3.2±0.2 nM and 1.6± 0.1 nM for human and canine, respectively.

HY-12241

AZ82	Inhibitor	99.31%
AZ82 is a selective kinesin-like protein KIFC1 (HSET/KIFC1) inhibitor, with a K_i of 43 nM and an IC₅₀ of 300 nM for KIFC1.

HY-101071A

Monastrol	Inhibitor	99.70%
Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5 with an IC₅₀ value of 14 μM.

HY-160441

MC-Val-Cit-PAB-Ispinesib	Inhibitor	99.85%
MC-Val-Cit-PAB-Ispinesib (Compound 509) is a potent inhibitor of Eg5. MC-Val-Cit-PAB-Ispinesib is a click chemistry reagent.

HY-15187C

Filanesib hydrochloride	Inhibitor
Filanesib (ARRY-520) hydrochloride is a selective and noncompetitive kinesin spindle protein (KSP) inhibitor, with an IC₅₀ of 6 nM for human KSP. Filanesib induces cell death by apoptosis in vitro. Filanesib has potent anti-proliferative activity.

HY-161112

LG157	Inhibitor
LG157 is a potent inhibitor of mitotic kinesin-like protein 2 (MKLP2).

HY-12069

SB-743921 hydrochloride	Inhibitor	99.87%
SB-743921 hydrochloride is a potent inhibitor of the mitotic kinesin KSP (Eg5), with a K_i of 0.1 nM.

HY-14846

Litronesib	Inhibitor	99.59%
Litronesib (LY2523355) is a selective mitosis-specific kinesin Eg5 inhibitor, with antitumor activity.

HY-W011102

S-Trityl-L-cysteine	Inhibitor	99.10%
S-Trityl-L-cysteine (NSC 83265) is a selective and allosteric kinesin Eg5 inhibitor with an IC₅₀ of 1 μM for the inhibition of basal ATPase activity and 140 nM for the microtubule-activated ATPase activity. S-Trityl-L-cysteine has antitumor activities.

HY-101298

Paprotrain	Inhibitor	99.87%
Paprotrain is a cell-permeable inhibitor of the kinesin MKLP-2, inhibits the ATPase activity of MKLP-2 with an IC₅₀ of 1.35 μM and a K_i of 3.36 μM and shows a moderate inhibition activity on DYRK1A with an IC₅₀ of 5.5 μM.

HY-15948

Kif15-IN-1	Inhibitor	99.39%
Kif15-IN-1 is an inhibitor of the mitotic Kinesin family member 15 (Kif15), and is used for the research of cellular proliferative diseases.

HY-15000

EMD534085	Inhibitor	99.55%
EMD534085 is a potent and selective inhibitor of the mitotic kinesin-5 with an IC₅₀ of 8 nM.

HY-15857

CW-069	Inhibitor	98.99%
CW-069 is an allosteric inhibitor of microtubule motor protein HSET with an IC₅₀ of 75 μM.

HY-19944

Dimethylenastron	Inhibitor	98.68%
Dimethylenastron is a potent kinesin Eg5 inhibitor, with an IC₅₀ of 200 nM.

HY-115570

GW406108X	Inhibitor	≥98.0%
GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC₅₀ of 0.82 uM in ATPase assays. GW406108X, a potent autophagy inhibitor, shows ATP competitive inhibition against ULK1 with a pIC₅₀ of 6.37 (427 nM). GW406108X inhibits ULK1 kinase activity and blocks autophagic flux, without affecting the upstream signaling kinases mTORC1 and AMPK.

HY-19530

PF-2771	Inhibitor	99.76%
PF-2771 is a potent and selective centromere protein E (CENP-E) inhibitor, inhibiting CENP-E motor activity with an IC₅₀ of 16.1 nM; PF-2771 is used as an anticancer agent.

HY-19966

K858 (Racemic)	Inhibitor	99.83%
K858 Racemic is an ATP-uncompetitive inhibitor of kinesin Eg5 with an IC₅₀ of 1.3 μM.

HY-122247

PVZB1194	Inhibitor	99.90%
PVZB1194 is a biphenyl-type inhibitor of Kinesin spindle protein Eg5 or KIF11. Eg5 is related to the cell cycle, and Eg5 inhibition can lead to cell cycle arrest and apoptosis. PVZB1194 exhibits anticancer potential via inhibiting Eg5 ATPase activity. PVZB1194 binds to the α4/α6 allosteric pocket, and shows ATP competetive activity.

Name
Email *

	Sorry, but the email address you supplied was invalid.